choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Isentress

Isentress Newsletter
  • 2024 First Generic Drug Approvals 23 Oct 2025 18:33 GMT

    … Labs Limited, Unit III Isentress Tablets 12/19… 123 Injection USP BWXT Medical Ltd AdreView Injection 12 … treatment of erectile dysfunction 38 215570 Palbociclib Tablets Synthon Pharmaceuticals, … 0.18 mg Indoco Remedies Limited Lucemyra (Lofexidine) …

  • Gilead’s HIV Combo on Hold, With No Impact on FDA's Pending Lenacapavir Decision 10 Jun 2025 18:13 GMT

    … trials for Gilead’s investigational weekly HIV combo pill … treatment of people with multi-drug-resistant HIV and currently under FDA … trial is comparing the combo with Gilead’s approved HIV medicine … arise. Merck, for example, had trials of Isentress, launched …

  • Lupin’s HIV generic gets FDA nod 09 May 2025 03:56 GMT

    … S. Food and Drug Administration (U.S. FDA) for its … Abbreviated New Drug Application (ANDA) … is bioequivalent to Isentress HD tablets, marketed by Merck Sharp & … , for the treatment of human immunodeficiency virus (HIV-1) infection …

  • HIV Diagnostics Market Projected To Hit USD 1.80 Billion By 2032, Driven By Rising Global Testing Rates And Technological Advancements | SNS Insider 10 May 2025 08:18 GMT

    … Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV … rising number of diagnostic treatments carried out. Conversely, … accessibility and accuracy in HIV diagnostics, especially in … Market Outlook Rapid Medical Diagnostic Kits Market …

  • Lupin wins USFDA okay for HIV-1 drug Raltegravir 09 May 2025 07:40 GMT

    … 39;s Abbreviated New Drug Application for Raltegravir Tablets … to Isentress HD Tablets, 600 mg of Merck Sharp … for the treatment of human immunodeficiency virus (HIV-1) … complex generics, biotechnology products, and active pharmaceutical ingredients. The …

  • Lupin receives US FDA approval for raltegravir tablets USP, 600 mg 08 May 2025 14:08 GMT

    … the United States Food and Drug Administration (FDA) for its Abbreviated New … are bioequivalent to Isentress HD tablets, 600 mg of Merck Sharp … agents for the treatment of human immunodeficiency virus (HIV-1) infection in …

  • Merck Announces First-Quarter 2025 Financial Results 24 Apr 2025 10:47 GMT

    … Drug Administration (FDA) granting Priority Review to Merck’s … as first-line treatment for adult … Trial (Read Announcement) Infectious Diseases Merck Announced Positive Data From Phase 3 Trials … are provided below. Pharmaceutical BRIDION (sugammadex) CAPVAXIVE …

  • HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR 18 Mar 2025 11:28 GMT

    … Merck initiated clinical trials for its next-generation HIV treatment targeting drug … and ART medications. Government … Merck & Co., Inc. Isentress … HIV treatment Teva Pharmaceutical Industries Ltd. Generic ARVs, Lamivudine, Zidovudine Growth in cos HIV Drugs …

  • HIV Treatment Information for Pregnant Women 30 Jan 2025 20:04 GMT

    … and are virologically suppressed (HIV-1 RNA less than 50 … and are virologically suppressed (HIV-1 RNA less than 50 … available for the approved treatment dose of 600 mg … information available Human Data Isentress Label Isentress HD raltegravir 600 mg …

  • Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results 04 Feb 2025 13:04 GMT

    … FDA Granted Priority Review to Merck’s Application for WELIREG for the Treatment … Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, … are provided below. Pharmaceutical BRIDION (sugammadex) CAPVAXIVE … -33 -28 Isentress/Isentress HD 111 89 …

Satisfied with the content?

Continue to create your account.